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Abstract
Background: Cancer chemoprevention is a new approach in cancer prevention, in which chemical
agents are used to prevent cancer in normal and/or high-risk populations. Although
chemoprevention has shown promise in some epithelial cancers, currently available preventive
agents are limited and the agents are costly, generally with side effects. Natural products, such as
grape seed, green tea, and certain herbs have demonstrated anti-cancer effects. To find a natural
product that can be used in chemoprevention of cancer, we tested Arizona cactus fruit solution,
the aqueous extracts of cactus pear, for its anti-cancer effects in cultured cells and in an animal
model.
Method: Aqueous extracts of cactus pear were used to treat immortalized ovarian and cervical
epithelial cells, as well as ovarian, cervical, and bladder cancer cells. Aqueous extracts of cactus pear
were used at six concentrations (0, 0.5, 1, 5, 10 or 25%) to treat cells for 1, 3, or 5 days. Growth
inhibition, apoptosis induction, and cell cycle changes were analyzed in the cultured cells; the
suppression of tumor growth in nude mice was evaluated and compared with the effect of a
synthetic retinoid N-(4-hydroxyphernyl) retinamide (4-HPR), which is currently used as a
chemoprevention agent. Immunohistochemistry staining of tissue samples from animal tumors was
performed to examine the gene expression.
Results: Cells exposed to cactus pear extracts had a significant increase in apoptosis and growth
inhibition in both immortalized epithelial cells and cancer cells in a dose- and time-dependent
manner. It also affected cell cycle of cancer cells by increasing G1 and decreasing G2 and S phases.
Both 4-HPR and cactus pear extracts significantly suppressed tumor growth in nude mice,
increased annexin IV expression, and decreased VEGF expression.
Conclusion: Arizona cactus pear extracts effectively inhibited cell growth in several different
immortalized and cancer cell cultures, suppressed tumor growth in nude mice, and modulated
expression of tumor-related genes. These effects were comparable with those caused by a
synthetic retinoid currently used in chemoprevention trials. The mechanism of the anti-cancer
effects of cactus pear extracts needs to be further studied.
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Background
The goal of cancer prevention is to delay or block the proc-
esses of initiation and progression from pre-cancerous
cells into cancer. Cancer chemoprevention, which targets
normal and high risk populations, involves the use of
drugs or other chemical agents to inhibit, delay, or reverse
cancer development [1,2]. There has been significant suc-
cess in the study of cancer prevention and chemopreven-
tion in the last 20 years [1,2] and, as a result, the
incidences of certain types of cancer have decreased due to
prevention techniques and improved screening technol-
ogy [1,2]. However, the incidence and mortality rates of
ovarian cancer have remained essentially unchanged [3],
partially because early detection methods (primary pre-
vention) have not been developed and prevention of
recurrence (secondary prevention) has not been achieved.
Furthermore, only a limited number of potentially useful
chemopreventive agent(s) have been tested [2,4-6]. Dis-
covery and development of dietary agents for cancer pre-
vention first began at the National Cancer Institute in
1987 [7]. Although hundreds of agents have been devel-
oped in the United States during the past decade, only a
few new drugs have actually been approved [7,8]. The
development of chemopreventive agents is slow and inef-
ficient. More effective and less toxic agents, including nat-
ural products, are needed if we are to reach the goal of
cancer prevention, both primary and secondary.
A synthetic retinoid, N-(4-hydroxyphernyl) retinamide
(4-HPR), was found to decrease the risk of ovarian cancer
in an Italian breast cancer chemoprevention trial [9-11].
Women receiving 4-HPR demonstrated a decreased inci-
dence of ovarian cancer [9,10]; however, after cessation of
the treatment, ovarian cancer did develop in the treatment
group [10,11]. Other studies have also reported that the
response of retinoids was not durable in pre-cancer and
cancer treatments for either oral leukoplakia or cervical
cancer [13-16]. These reports suggest that long-term
administration of agents with lower toxicity will be the
most important aspect in chemopreventive agents, espe-
cially for normal and high risk populations.
Medical benefits from plant forms have been recognized
for centuries. Herbs have been used in Chinese medicine
for thousands of years to cure diseases and heal wounds.
Recently, it has been found that components in green tea
and grape seeds have anticancer effects [17,18]. Also, as a
rule, herbs and natural products lack much of the toxicity
that is present in synthetic chemicals, thus, enhancing
their appeal for long term preventive strategies.
Cactus (Opuntia) has been used for many years as a com-
mon vegetable and as medicine by the Native Americans
and Mexicans [19-22]. Cactus contains a fruit known as
cactus pear (Opuntia ficus-indica) and the plant is referred
to as nopale (pad). Cactus pear contains pectin, carotenes,
betalains, ascorbic acid, quercetina and quercetin deriva-
tives all of which have antioxidant activity [21-24]. In Chi-
nese medicine, cactus fruit is considered a weak poison
and used as medicine for treatment of inflammation and
pain [23,24]. It has also been used as a detoxification
agent for snake bite [23,24].
In this study, we tested aqueous extracts of cactus pear for
its anti-cancer effects in ovarian, cervix, and bladder can-
cer cells, and in the nude mice ovarian animal model.
These results were compared to the effect of 4-HPR, dem-
onstrated the anti-cancer effect of the cactus pear.
Methods
Cell lines
The immortalized ovarian epithelium cells (IOSE), the
ovarian cancer cell lines OVCA420, SKOV3; the HPVE6
immortalized cervical epithelium cell line TCL-1; cervical
cancer cell lines, HeLa and Me180; and bladder cancer
cells UM-UC-6, T24, were all used in this study. Cells were
grown in a 1:1 (v/v) mixture of Dulbecco's modified
Eagle's medium (DMEM) and Ham's F12 with 10% fetal
bovine serum at 37°C in a humidified atmosphere of
95% air and 5% CO2.
Animals
Athymic 4 to 6 weeks old nu/nu BALB/c female mice were
purchased from the Animal Production Area at the
National Cancer Institute, Frederick Cancer Research
Facility (Frederick, MD). The mice were housed in laminar
flow cabinets under pathogen-free conditions and main-
tained at the University of Arizona's Animal Care Facility
in the College of Medicine, according to institutional reg-
ulations approved by the Animal Welfare Committee as
well as current regulations and standards of the Depart-
ment of Agriculture and the Department of Health and
Human Services.
Cactus product
The cactus pear extract was purified from mature cactus
fruit by blending. The cactus pear solution contained both
the fruit of the cactus and the seeds, and were centrifuged
at 4,000 RPM for 30 min and filtered using a 0.45 µM Nal-
gene filter (Rochester, NY), then aliquoted to 15 ml and
stored at -20°C. We used pure extracts which were diluted
in cell culture medium to achieve concentrations of 0, 0.5,
1, 5, 10 and 25% (v/v), before being used in cell culture.
The osmolality of the solution was 358 m Osm/kg for
25% solution, 342 m Osm/kg for 10%, and 326 m Osm/
kg for 5%. The pH was between 7.26–7.28. Animals were
treated with pure cactus pear fruit intraperitoneally (i.p.)
at 0.4 ml per day.Nutrition Journal 2005, 4:25 http://www.nutritionj.com/content/4/1/25
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Effects of cactus products on cell proliferation in 
monolayer cultures
Cells were plated in 96-well plates at a concentration of
104 cells per well and grown for 24 hours. The cells were
then incubated in cactus pear solution at different concen-
trations for 1, 3, or 5 days. Growth inhibition was deter-
mined using the crystal violet method, as described [25].
Briefly, after 5 days of treatment, cells were fixed by 5%
glutartaldehyde in phosphate-buffered saline (PBS),
rinsed with distilled water, and dried completely. Cells
were incubated in a 1:1 (v/v) mixture of 200 mM 3-
(cyclohexylamino)-1-propanesulfonic acid (CAPS; pH
9.5) and 0.2% crystal violet at 25°C for 30 min, and then
were washed and dried. The fixed and stained cells were
solubilized with 10% glacial acetic acid, and absorbance
at A590 nm was determined using a plate reader. Growth
inhibition was calculated according to the equation: inhi-
bition = (1-Nt/Nc) × 100, where Nt and Nc are the num-
bers of cells in treated and control cultures, respectively.
All experiments were performed in triplicate and the
mean ± standard deviations were calculated. IC50 were
also determined at 50% of cell growth rate in each.
Cell cycle analysis by propidium iodide (PI) staining
Cells were treated with 0, 5 and 25% of cactus pear solu-
tion for 2 days, were collected by centrifugation and fixed
in 4% paraformaldehyde pH 7.4 at room temperature for
30 min, and washed and incubated in 70% ethanol con-
taining 1% HCl at -20°C for 10 minutes. Cells were then
stained with 500 µl of propidium iodide/RNase A solu-
tion in the dark for 30 min at room temperature, analyzed
by flow cytometry using a FACScan flow cytometer (BD
Biosciences, San Jose, CA) with a 15 mW Argon laser used
for excitation at 488 nm. Fluorescence was measured at
585 nm. Computer analysis was completed using BD Bio-
sciences Cellquest Pro and ModFit LT by Verity Software
data processing to provide information on the percentage
of apoptotic cells as well as the proportion of cells in G1,
S, and G2 phases of the cell cycle.
Analysis of apoptosis induced by cactus product by 
terminal deoxynucleotidyl transferase (TdT)-mediated 
fluorescein-deoxyuridine-triphosphate (dUTP) nick-end 
labeling (TUNEL) assay [25]
Following incubation with 0, 5, and 25% cactus pear solu-
tion for 2 days, cells were fixed in 1% formaldehyde in
PBS (pH 7.4) for 15 min at 4°C. The cells were then
washed twice with PBS, resuspended in 70% ice-cold eth-
anol and stored in a -20°C freezer until use. For the assay,
cells were first suspended in 1 ml wash buffer containing
cacodylic acid, Tris-HCl buffered solution and sodium
azide (Phoenix flow cytometry kit, Phoenix Flow Systems,
San Diego, CA). Approximately 106  cells were resus-
pended in 50 µl staining buffer containing Tris-HCl
buffer, TdT, and fluorescein-12-dUTP (Phoenix flow
cytometry kit). Cells were incubated at 37°C for 60 min,
and then rinsed twice with PBS. Cells were stained with
500 µl of propidium iodide/RNase A solution in the dark
for 30 min at room temperature and then analyzed by
flow cytometry using a FACScan flow cytometer (Epics
Profile, Coulter Corp., Hialeah, FL) with a 15 mW argon
laser used for excitation at 488 nm. Fluorescence was
measured at excitation 520 nm and 570 nm. The Phoenix
flow cytometry kit included suspensions of cells that
served as negative and positive controls for apoptosis.
Computer analysis of the data provided information on
the percentage of apoptotic cells as well as the proportion
of cells in the hypodiploid, G1, S, and G2 phases of the cell
cycle.
Human tumor xenografts
Ovarian cancer cells SKOV3 were grown to sub-conflu-
ence and harvested using 0.1% trypsin and 1 mM EDTA.
The cells were washed with serum containing medium to
quench the trypsin and then with serum-free medium.
Cell viability was determined by Trypan blue exclusion
and only cultures with more than 90% viability were used
for the in vivo experiments. The cells were resuspended in
medium at 5 × 106 cells. Cactus pear solution, as well as
the chemopreventive agent 4-HPR (0.43 mg i.p twice/
week, which equivalent to 200 mg/kg human dose) were
injected one day prior to tumor cell injection (day 1) (Fig.
Cactus pear extracts treatment schedule in animal Figure 1
Cactus pear extracts treatment schedule in animal. Numbers 
of injection times/week were represented by arrow bars. 
Four groups of animal were examined in the study: SKOV3 
alone, SKOV3 + H2O, SKOV3 + Cactus extracts, and 
SKOV3 + 4HPR. 4-HPR concentration was used at 0.43 mg/
kg, which equivalent to human 200 mg/kg.
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Effect of cactus pear extracts on growth of human cervical, ovarian, and bladder cancer cells in monolayer cultures Figure 2
Effect of cactus pear extracts on growth of human cervical, ovarian, and bladder cancer cells in monolayer cultures. Cells were 
grown for 1, 3, or 5 days in the absence (control) or presence of 0.5, 1, 5, 10, or 25% of cactus pear extracts in (a.) immortal-
ized cervical cells and cervical cancer cells; (b.) immortalized ovarian cells and ovarian cancer cells; and (c.) bladder cancer cells. 
Values are means ± SD of triplicate cultures. The percentage of growth inhibition (GI) was calculated using the equation: % GI 
= (1-Nt/Nc) × 100; where Nt and Nc represent the numbers of cells in treated and control cultures, respectively.
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1). Control animals received H2O. Tumor cells were
injected subcutaneously (day 2). The tumors appeared on
day 10–14, and their size was measured twice a week
using a caliper. The larger (A) and smaller (B) diameters
were used to calculate the tumor volume (V) by using the
equation V = 0.4 × A × B2 [27]. The treatment regimen of
cactus pear solution was as follows: 0.4 ml of solution
injected i.p. twice a week for the first two weeks, then five
times a week from the third week to the sixth week (Fig.
1).
Immunostaining
Paraffin-embedded sections were deparaffinized in
xylene, rehydrated through graded alcohols to water, then
incubated for 10 min in PBS. The sections were blocked
for 30 min with 3% normal horse serum (NHS) diluted in
PBS; the sections were then blotted and incubated with
p53, annexin IV and VEGF antibodies (Santa Cruz Bio-
tech, Santa Cruz, CA, and Zymed Lab Inc, San Francisco,
CA) for 1 hr at room temperature. The endogenous perox-
idase was inactivated by incubation for 30 min in 0.015%
peroxide in methanol and rehydrated for 10 min in PBS.
The slides were incubated with biotinylated horse anti-
body for 1 hr and washed in PBS, followed by the avidin-
biotin-peroxidase complex (ABC, Vector Laboratories,
Burlingame, CA). The slides were washed and the peroxi-
dase reaction developed with diaminobenzidine and
peroxide, then counterstained with hemotoxylin,
mounted in aqua-mount, and evaluated on a light micro-
scopy. Positive and negative antibodies and bladder and
ovarian cancer cells were used as controls in each assay.
Statistical analysis
Student's t test was performed to compare two means.
One-way ANOVA, followed by the Fisher's Least Square
Difference (LSD) test, was used to analyze tumor size in
different treatment groups or multiple means. Two-sided
P values were determined in all analyses. P < 0.05 is con-
sidered as statistically significant.
Results
Growth inhibitory effect of cactus pear solution on human 
ovarian cell lines
Cactus pear extracts were used at different concentrations
(see Methods) to compare the inhibitory effect on a
growth of 3 different types of human cancer cells in
Effect of cactus pear extracts on the morphology of cervical cells Figure 3
Effect of cactus pear extracts on the morphology of cervical cells. Immortalized cervical cells and cervical cancer cells were 
grown in the absence (control) or presence of different concentrations of cactus extracts. The photographs were taken on day 
3 after the removal of medium containing floating cells.
Cactus extracts 0% 1% 5% 10% 25%
TCL-1
HeLa
Me180Nutrition Journal 2005, 4:25 http://www.nutritionj.com/content/4/1/25
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Effect of cactus pear extracts on the morphology of ovarian cells Figure 4
Effect of cactus pear extracts on the morphology of ovarian cells. Immortalized ovarian cells and ovarian cancer cells were 
grown in the absence (control) or presence of different concentrations of cactus extracts. The photographs were taken on day 
3 after the removal of medium containing floating cells.
Effect of cactus pear extracts on the morphology of bladder cancer cells Figure 5
Effect of cactus pear extracts on the morphology of bladder cancer cells. Bladder cancer cells were grown in the absence (con-
trol) or presence of different concentrations of cactus extracts. The photographs were taken on day 3 after the removal of 
medium containing floating cells.
IOSE
SKOV3
OVCA420
cactus extract 0% 1% 5% 10% 25%
Cactus extracts 0% 1% 5% 10% 25%
T24
UM-UC-6Nutrition Journal 2005, 4:25 http://www.nutritionj.com/content/4/1/25
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monolayer cultures. The sensitivity of cancer cells to cac-
tus treatment differed among cell types. Cervical cancer
cells were the most sensitive compared with ovarian and
bladder cancer cells (Fig. 2a,b,c). One percent (1%) cactus
pear solution inhibited 40–60% of immortalized cervical
epithelium cells and cervical cancer cells (Fig. 2a). For
ovarian cancer cells, 5% cactus pear solution was effective
on growth inhibition in IOSE and OVCA420 cells, how-
ever, 10% solution was required to inhibit growth in
SKOV3 cells (Fig. 2b). The concentration of cactus pear
extracts effect on 50% of bladder cancer cell growth was
greater than 1% (Fig. 2c). The effect of the cactus pear
solution was dose-and time-dependent (Fig. 2). The IC50
(the concentration causing 50% cell death) in cervical and
bladder cancer cells after 5-day treatment with cactus pear
solution was less than 2 percent. For cervical cells, the
IC50 for TCL-1 was 1.5%; HeLa was 1.8%; and ME180
was 0.8%. For bladder cancer cells, IC50 was 0.9% and
1.3% for UM-UC-6 and T24 cells, respectively. However,
the IC50 for ovarian cells was varied, IC50 for IOSE,
OVCA420, and SKOV3 cells were 2%, 0.8%, and 8%,
respectively. Morphological changes were induced by cac-
tus pear extracts 3 days after treatment and were in con-
cordance with the agent's effect on cell growth of cervical
cells (Fig. 3), ovarian cells (Fig. 4), and bladder cancer
cells (Fig. 5).
Apoptosis induction by cactus extract in different cancer 
cells
Cactus pear solution induced apoptosis in all three cancer
cell lines tested by TUNEL analysis (Fig. 6 and 7). In can-
cer cell lines, the strongest effect of apoptosis induction
was found in cervical cells. The apoptosis cell population
increased by more than 50% at the concentration of 25%
cactus extract compared with the untreated cells (Fig. 6).
This was consistent with cell growth inhibitory effects
(Fig. 2 and 6). The immortalized cervical epithelium cells
were the most sensitive in which the apoptotic cells
increased over 70% after treatment (Fig. 6). Apoptosis
induction in ovarian and bladder cancer cells differed: in
Apoptosis induction analyzed by TUNEL assay in cervical cells Figure 6
Apoptosis induction analyzed by TUNEL assay in cervical cells. Cells were treated with 5% and 25% cactus pear solution for 2 
days. Cells were harvested and incubated with TdT in the presence of biotin-labeled BrdU and analyzed by flow cytometry. 
The percentage of apoptotic cells is represented by dark dots (fluorescence of individual cells) above the line in R3 region (R3 
is the computer software analysis apoptosis program).
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ovarian cancer cells, cactus extracts increased apoptosis
induction from 40% to 50% in OVCA420 and SKOV3
cells (Fig. 7, left and mid-panel). In T24 bladder cancer
cells, apoptosis was 30% (Fig. 7, right panel). Apoptosis
induction was not significant at 5% concentration.
Cell cycle and apoptosis analysis in cancer cells
DNA content and cell cycle analysis were performed after
treatment with 0, 5, and 25% concentrations of cactus
pear solution. Results demonstrated that cactus pear
extracts affected cell cycle in cancer cells starting at a 5%
concentration (Fig. 8a, and 8b). In cervical cancer cells,
cactus extracts increased cells in G1 and decreased those in
the S phase (Fig. 8a). Treatment with higher concentra-
tions of cactus pear extracts increased cells in G1 and
decreased cells in G2 and in the S phase in ovarian and
bladder cancer cells (Fig. 8b). The effect of cactus on cell
cycle was dose-dependent.
Cactus products inhibited tumor growth in a nude mice 
model
The treatment groups and the schedule of treatment are
shown in Fig. 1. Animal body weight was measured twice
a week for weight loss, as an indication of toxicity. Cactus
pear extracts had no significant effect on weight loss (Fig.
9a) or animal behavior.
The cactus pear solution was able to inhibit tumor growth
in nude mice compared with that in untreated animals or
animals treated with H2O (Fig. 9b). The effect of cactus
pear solution on inhibiting tumor growth indicated by
tumor size was compared with 4-HPR, which is currently
being used as a chemopreventive agent in ovarian, cervical
and bladder cancer clinical trials [11-17] (Fig. 9b). We
compared the control animal transplanted with SKOV3
cells only and SKOV3 + H2O to treatment group with
either cactus pear extracts or 4-HPR. Cactus pear extracts
and 4-HPR significantly reduced tumor size (p < 0.05).
The inhibitory effect of 4-HPR was not significantly differ-
ent from that of the cactus pear extract solution (p > 0.05).
Apoptosis induction analyzed by TUNEL assay in ovarian and bladder cancer cells Figure 7
Apoptosis induction analyzed by TUNEL assay in ovarian and bladder cancer cells. TUNEL analysis results showed apoptosis 
induction by cactus extract in ovarian cancer cells (left and mid-panel) and bladder cancer cells (right panel).
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Immunohistochemistry staining for p53, annexin IV and 
VEGF expression
The expression of p53, annexin IV, and VEGF were exam-
ined in animal tumor tissues. 4-HPR and cactus extracts
treatment increased annexin IV and decreased VEGF
expression; also cactus extracts had a stronger effect on
suppression of VEGF expression (Fig. 10). Both 4-HPR
and cactus extracts slightly changed p53 expression, where
more negative nuclei were observed (Fig. 10).
Discussion
Remarkable progress has been made over the past two
decades in understanding the molecular and cellular
mechanisms of pre-cancer and cancer progression [2].
Nonetheless, the development of effective and safe agents
for prevention and treatment of cancer remains slow, inef-
ficient, and costly [7], with little to offer the high-risk pop-
ulation for primary prevention and cancer survivors to
prevent cancer recurrence. The key to effective chemopre-
vention is the identification of a chemopreventive
agent(s) that can effectively inhibit cancer development
without toxic side effects. In an Italian 4-HPR trial, retin-
oids showed the preventive effect on ovarian cancer only
during the period while the drug was taken. After cessa-
tion of treatment, the incidence of ovarian cancer
increased to the level that was observed in the untreated
control group [10,11]. Therefore, chemopreventive agents
may need to be used for a long period of time to be
effective. As a result, identification of agents with little or
no toxicity becomes important. We have shown that cac-
tus pear extracts, a natural product, has anti-cancer activ-
ity, although the active component(s) have not been
clearly identified. Since it has no toxic effects, cactus pear
extracts can be easily used, for example, as dietary supple-
ments [19-21] in normal and high risk populations.
Cell cycle analysis Figure 8
Cell cycle analysis. Cells were treated with 5 and 25% cactus pear extract for 2 days. Cells were stained with propidium iodide/
RNase A solution for 30 min then analyzed by flow cytometry using a FACScan flow cytometer. (a.) cervical cancer cells HeLa 
and Me180; (b.) ovarian cancer cells SKOV3 and OVCA420 (upper), and bladder cancer cells T24 (bottom).
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It has been noted that Native Americans have a lower can-
cer rate when compared to white and African Americans
[3]. Both cactus pear and nopale which contain multiple
antioxidants, have been used as a dietary supplement for
centuries by Native Americans. Our results show that the
cactus pear inhibited growth of different cancer cells in
vitro  and  in vivo. Cactus products inhibited cancer cell
growth with concentrations as low as 5%; cell cycle was
also affected at this concentration with an increase in G1
phase (Fig 2 and 8). However, apoptosis was observed at
a higher concentration of 10% (data not shown) and 25%
(Fig. 6 and 7).
We also compared cactus with the chemopreventive agent
4-HPR in nude mice. Both cactus and 4-HPR inhibited
ovarian cancer growth. The anti-carcinogenic properties of
natural and synthetic retinoids have been suggested to be
due, in part, to the antioxidant effect [28-30], increased
consumption of fruit and vegetables is associated with
prevention of various human diseases, and the oxidative
damage is an important etiologic risk factor for many dis-
eases, including cancer and heart disease. Cactus pear
extracts also contain multiple antioxidants that can reduce
oxidative damage. The clinical trial on vitamin C and cac-
tus pear demonstrated that supplements of vitamin C at a
comparable dosage enhances overall antioxidant defense
but does not significantly affect body oxidative stress
[21,22]. Components of cactus pear extract, other than
antioxidant vitamins, may play a role in anti-oxidant
effects [21,22,31-33].
Carcinogenesis may be viewed as a process of progressive
disorganization. This process is characterized by the
accumulation of genotypic changes and corresponding
tissue and cellular abnormalities including loss of
proliferation and apoptosis controls. A dietary agent that
can increase anti-proliferation pathways and change cell
cycle in cancer cells without toxicity would be a potential
agent for chemoprevention. Although the mechanism for
cactus pear extract in cancer prevention is unclear, our
current study shows that cactus pear does alter the expres-
sion of certain genes related to cell growth and apoptosis.
Cactus pear extracts increased annexin IV and decreased
VEGF expression in animal tumors. Annexin IV, a Ca2+-
dependent membrane-binding protein, is expressed in
many epithelial cancers [34]. Annexin IV played a pivotal
role in the early phases of apoptosis [35], it was identified
in initiation of apoptosis in human preneoplastic colono-
cytes [35], and its expression was regulated by quercetin
[35]. Quercetin is one of the components of cactus pear
extracts. Our results (unpublished data) and other reports
[35,36] suggest quercetin might be one of the active
compounds responsible for the anti-carcinogenetic and
apoptosis-induction effects of cactus pear extracts. In our
study, cactus pear extracts decreased VEGF expression,
suggesting that cactus pear extracts might have inhibitory
a. Animal body weight curve Figure 9
a. Animal body weight curve. The body weight was measured twice a week during the experiment. The picture represents the 
control animal labeled as H2O and treated-animal as SKOV3 only (SKOV3), SKOV3 + cactus pear (pear sol), and SKOV3 + 
4HPR (4-HPR). b. Tumor growth curve. Tumor size in cactus pear and 4-HPR treatment groups, compared with control 
SKOV3 only and SKOV3 plus H2O, was significantly reduced (p < 0.05). The effect of cactus pear solution compared with 4-
HPR on inhibiting tumor growth, both agents were able to inhibit SKOV3 inoculated tumor growth, the difference is not statis-
tically significant (p > 0.05).
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effects on angiogenesis, an important factor contributing
to tumor growth and metastasis. We did not observe a sig-
nificant effect on p53 expression caused either by 4-HPR
or cactus pear extracts. Mutation of p53 is expected with
the SKOV3 cell line, the tumor cells used in this animal
model [37,38] but in this study, we observed minimal
effect on p53 expression after treated with cactus extract
and 4-HPR. However, since both wild-type and mutant
p53 could contribute to induction of apoptosis,
involvement of p53 pathway by 4-HPR or cactus pear
extract cannot be ruled out by these results.
For developing food-derived agents, the NCI has advo-
cated co-development of a single or purified extract of a
few putative active compounds that are contained in
food-derived agents [7]. The cactus pear extracts tested in
this study could be such a candidate in cancer prevention
for both normal and high-risk populations and preven-
tion of recurrence in patients with previous cancers. This
product holds promise for long-term use because of the
safety of food-derived products and the fact that they are
not perceived as a "chemical".
Conclusion
Arizona prickly pear cactus effectively inhibited cell
growth in several different immortalized and cancer cell
cultures in vitro and suppressed tumor growth in a nude
mouse of ovarian cancer model. The mechanism of anti-
cancer effect of cactus pear extracts is not yet completely
understood. Currently, we are investigating the expression
of genes related to cell growth and apoptosis which may
be altered by treatment with cactus products to elucidate
possible pathways through which this natural product
exerts its anti-cancer effects.
Representative immunohistochemistry patterns of p53, annexin IV and VEGF in animal tumor sections Figure 10
Representative immunohistochemistry patterns of p53, annexin IV and VEGF in animal tumor sections. p53 expression was 
stained as positive (+) in SKOV3 only and SKOV3 plus H2O groups, treatment of 4-HPR was slightly changes its expression and 
most of nuclei were stained negative (upper panel). Cactus extract treatment was found in some of nuclei stained negative 
(weak). Annexin IV expression was detected negatively (-) in SKOV3 only and SKOV3 plus H2O groups, treatment of both 4-
HPR and cactus extracts were increased its expression (mid panel). VEGF expression was detected positively (+) in SKOV3 
only and SKOV3 plus H2O groups, treatment of both 4-HPR and cactus extracts were decreased its expression (bottom 
panel).
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